| scholarly article | Q13442814 |
| P50 | author | Hiroyuki Aburatani | Q87657008 |
| P2093 | author name string | Yasuhide Yamada | |
| Naoki Takahashi | |||
| Hidekazu Takahashi | |||
| Shin Takahashi | |||
| Chikashi Ishioka | |||
| Masanobu Takahashi | |||
| Kenji Tatsuno | |||
| Hideki Shimodaira | |||
| Kota Ouchi | |||
| Shingo Tsuji | |||
| P2860 | cites work | Global cancer statistics | Q22241238 |
| CpG island methylator phenotype in colorectal cancer | Q24672170 | ||
| Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer | Q27851407 | ||
| KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. | Q27851422 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer | Q27851456 | ||
| Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis | Q27851573 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial | Q28036747 | ||
| FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study | Q28189472 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer | Q28271324 | ||
| Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 | ||
| CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer | Q29614277 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Three DNA methylation epigenotypes in human colorectal cancer | Q33520394 | ||
| Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer | Q33913953 | ||
| A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. | Q34282412 | ||
| Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. | Q34590731 | ||
| Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. | Q34624122 | ||
| PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color | Q34660907 | ||
| FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial | Q34663697 | ||
| Genome-scale analysis of aberrant DNA methylation in colorectal cancer | Q35694387 | ||
| CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies | Q35760749 | ||
| Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up | Q37489147 | ||
| The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status | Q38417609 | ||
| A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer | Q39450048 | ||
| DNA methylation analysis by digital bisulfite genomic sequencing and digital MethyLight | Q39853397 | ||
| Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801). | Q54342085 | ||
| Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. | Q54568648 | ||
| Sessile serrated adenoma (SSA) vs. traditional serrated adenoma (TSA) | Q80418165 | ||
| Genome-wide identification of possible methylation markers chemosensitive to targeted regimens in colorectal cancers | Q84785186 | ||
| P433 | issue | 12 | |
| P921 | main subject | colorectal cancer | Q188874 |
| biomarker | Q864574 | ||
| DNA methylation | Q874745 | ||
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | 1722-1729 | |
| P577 | publication date | 2015-10-01 | |
| P1433 | published in | Cancer Science | Q326125 |
| P1476 | title | DNA methylation status as a biomarker of anti-epidermal growth factor receptor treatment for metastatic colorectal cancer | |
| P478 | volume | 106 |
| Q37725589 | ATM mutations and E-cadherin expression define sensitivity to EGFR-targeted therapy in colorectal cancer. |
| Q97525750 | Anti-EGFR therapy in metastatic colorectal cancer: mechanisms and potential regimens of drug resistance |
| Q37321131 | Blood-based markers of efficacy and resistance to cetuximab treatment in metastatic colorectal cancer: results from CALGB 80203 (Alliance) |
| Q55124199 | Consensus molecular subtypes classification of colorectal cancer as a predictive factor for chemotherapeutic efficacy against metastatic colorectal cancer. |
| Q50607666 | CpG island methylator phenotype is associated with the efficacy of sequential oxaliplatin- and irinotecan-based chemotherapy and EGFR-related gene mutation in Japanese patients with metastatic colorectal cancer. |
| Q52536411 | DNA methylation as a marker of response in rheumatoid arthritis. |
| Q55342871 | Optimising the use of cetuximab in the continuum of care for patients with metastatic colorectal cancer. |
| Q38805790 | Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer |
Search more.